Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Radius Health Reports Positive Phase 3 Cancer Treatment Trial Results

Published 2021-10-20, 12:38 p/m
Updated 2021-10-20, 12:38 p/m
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Radius Health (NASDAQ:RDUSand the Menarini Group announced positive topline results from their study of a treatment for advanced or metastatic breast cancer.

Radius shares rose 21% on Wednesday. 

The study was designed to assess the treatment, elacestrant, as a monotherapy versus the standard of care for the disease. 

There were two primary endpoints for the study, which were both met— progression-free survival in the overall population and progression-free survival in patients with tumors harboring estrogen receptor 1 mutations.

“We are extremely excited as elacestrant is the first oral SERD to show positive topline results in a pivotal trial as a monotherapy vs SoC for the treatment of ER+HER2-advanced or mBC,” said Elcin Barker Ergun, CEO of the Menarini Group.

Elacestrant received fast track designation from the Food and Drug Administration in 2018, and the companies said they will now progress with regulatory submissions in both the U.S. and EU in 2022. 

There were 466 patients in the study, including 220 with tumors harboring an Estrogen Receptor 1 mutation. 

Radius’ CEO, Kelly Martin, commented: “Completing the EMERALD trial was a tremendous effort given the myriad of Covid related obstacles across the globe. Our collective teams did an outstanding job delivering the results of the trial in a high-quality and, ultimately, successful manner.”

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.